Swiss National Bank Reduces Holdings in Hologic, Inc. (NASDAQ:HOLX)

Swiss National Bank lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 692,740 shares of the medical equipment provider’s stock after selling 2,200 shares during the period. Swiss National Bank owned about 0.30% of Hologic worth $56,431,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Wolff Wiese Magana LLC purchased a new stake in Hologic in the 3rd quarter valued at approximately $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic during the second quarter valued at $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the first quarter valued at $37,000. Sunbelt Securities Inc. acquired a new position in Hologic in the 2nd quarter valued at about $37,000. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the topic of several analyst reports. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. UBS Group increased their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Down 0.3 %

Shares of NASDAQ:HOLX opened at $78.57 on Wednesday. The stock has a 50-day simple moving average of $80.56 and a 200-day simple moving average of $78.30. The stock has a market capitalization of $18.25 billion, a P/E ratio of 23.59, a PEG ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.